Stay updated on Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial

Sign up to get notified when there's something new on the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:11:03.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the treatment protocol for patients with metastatic castrate resistant prostate cancer, involving the administration of nivolumab and ipilimumab based on specific immunogenic signatures.
    Difference
    0.1%
    Check dated 2024-06-06T14:31:46.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide a more detailed explanation of eligibility criteria, including examples such as general health condition or prior treatments. The new description emphasizes the importance of these criteria in selecting participants for clinical research.
    Difference
    31%
    Check dated 2024-05-22T20:57:59.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:21:18.000Z thumbnail image

Stay in the know with updates to Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page.